AR132064A1 - Anticuerpos anti-cldn6 y métodos de uso - Google Patents
Anticuerpos anti-cldn6 y métodos de usoInfo
- Publication number
- AR132064A1 AR132064A1 ARP240100554A ARP240100554A AR132064A1 AR 132064 A1 AR132064 A1 AR 132064A1 AR P240100554 A ARP240100554 A AR P240100554A AR P240100554 A ARP240100554 A AR P240100554A AR 132064 A1 AR132064 A1 AR 132064A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- antibody
- binding fragment
- binding
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente divulgación proporciona anticuerpos y fragmentos de unión a antígeno de los mismos que se unen a CLDN6 humanos, una composición farmacéutica que comprende dicho anticuerpo o fragmentos de unión a antígeno de los mismos, y el uso del anticuerpo o fragmentos de unión a antígeno de los mismos o la composición para tratar una enfermedad, como el cáncer. Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno del mismo, que comprende un dominio de unión a antígeno que se une específicamente a la claudina 6 humana (CLDN6). Reivindicación 18: Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno, de acuerdo con cualquiera de las reivindicaciones 1 a 17 que comprende además un portador farmacéuticamente aceptable. Reivindicación 28: Un ácido nucleico aislado que codifica el anticuerpo o fragmento de unión a antígeno de acuerdo con cualquiera de las reivindicaciones 1 a 17. Reivindicación 29: Un vector que comprende el ácido nucleico de acuerdo con la reivindicación 28. Reivindicación 30: Una célula huésped que comprende el ácido nucleico de acuerdo con la reivindicación 28 o el vector de acuerdo con la reivindicación 29. Reivindicación 31: Un procedimiento para producir un anticuerpo o un fragmento de unión a antígeno del mismo que comprende cultivar la célula huésped de acuerdo con la reivindicación 30 y recuperar el anticuerpo o el fragmento de unión a antígeno del cultivo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023079815 | 2023-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR132064A1 true AR132064A1 (es) | 2025-05-21 |
Family
ID=90363964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100554A AR132064A1 (es) | 2023-03-06 | 2024-03-05 | Anticuerpos anti-cldn6 y métodos de uso |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR132064A1 (es) |
| TW (1) | TW202436354A (es) |
| WO (1) | WO2024184812A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119462928B (zh) * | 2024-11-08 | 2025-09-05 | 深圳豪石生物科技有限公司 | 特异性靶向cldn6的抗体及其在制备car-t细胞中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR20140053410A (ko) | 2005-08-19 | 2014-05-07 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| EP3026064B1 (en) * | 2011-05-13 | 2018-10-17 | Ganymed Pharmaceuticals GmbH | Antibodies for treatment of cancer expressing claudin 6 |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| DK3107938T3 (da) | 2014-05-28 | 2022-07-11 | Zymeworks Inc | Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf |
| CN108283001B (zh) | 2015-10-08 | 2022-08-19 | 酵活有限公司 | 包含κ和λ轻链的抗原结合多肽构建体及其用途 |
| MX2019002242A (es) | 2016-08-26 | 2019-08-16 | Beigene Ltd | Anticuerpos anti-tim-3 y uso de los mismos. |
| TWI877769B (zh) | 2017-12-30 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
| CN112566935B (zh) | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| EP4305067A1 (en) * | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
-
2024
- 2024-03-05 WO PCT/IB2024/052127 patent/WO2024184812A1/en not_active Ceased
- 2024-03-05 AR ARP240100554A patent/AR132064A1/es unknown
- 2024-03-05 TW TW113107891A patent/TW202436354A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202436354A (zh) | 2024-09-16 |
| WO2024184812A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111203A1 (es) | Inmunoconjugados | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| BR112022017174A2 (pt) | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor | |
| CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| BR112023020371A2 (pt) | Anticorpo anti-adgre2 humanizado ou fragmento de ligação ao antígeno do mesmo, método de tratamento de um câncer, composição farmacêutica, sequência de ácido nucleico, vetor, célula isolada, e, método de tratamento de câncer | |
| AR131527A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| MX2023014866A (es) | Direccionamiento selectivo de celulas alorreactivas cd70+ huesped para prolongar la persistencia de las celulas t con car alogenicas. | |
| CO2023016037A2 (es) | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos | |
| AR132041A1 (es) | Anticuerpos cd16a y métodos de uso | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR130129A1 (es) | Constructos de unión a cd98 para tratar tumores cerebrales | |
| AR132063A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso | |
| AR132062A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso | |
| AR132040A1 (es) | Anticuerpos muc1 y cd16a y métodos de uso | |
| PE20251175A1 (es) | Anticuerpos anti-bmp9 y metodos de uso de los mismos | |
| AR130172A1 (es) | Anticuerpos anti-pvrig y métodos de uso | |
| AR132043A1 (es) | Anticuerpos muc1 y métodos de uso | |
| UY39687A (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo | |
| AR133427A1 (es) | Anticuerpos anti-gprc5d y composiciones | |
| MX2025005847A (es) | Anticuerpos anti-cd137 y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |